Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 9/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7271583 | 0.88 | CTSK (0.38) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL20468220 | 0.87 | AAK1 (0.41) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL8836642 | 0.82 | TDP1 (0.42) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL88462 | 0.82 | CTSK (0.41) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL18482537 | 0.81 | MEN1 (0.34) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL7279185 | 0.81 | MEN1 (0.39) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL28672286 | 0.81 | MEN1 (0.39) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL2279581 | 0.81 | MEN1 (0.39) | MEN1GAAKMT2AAPLNRCTSS | |
| SCHEMBL10926854 | 0.81 | MEN1 (0.35) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL5408412 | 0.79 | CTSK (0.41) | MEN1GAAKMT2ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1497317-B1 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060167268-A1 | Growth hormone secretagogues | ELI LILLY AND COMPANY, PATENT DIVISION, (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1497316-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050240001-A1 | 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1497317-A2 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087069-A2 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167268-A1 | Growth hormone secretagogues | GHSR, GHRHR, CRH | MEN1 119/4885GAA 251/4885KMT2A 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.